Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. A. Ghofrani, N. Galiè, F. Grimminger, M. Humbert, A. M. Keogh, L. J. Rubin, M. Sikirica, A. Fritsch, N. Davie, S. Hudgens, N. Bonner, B. Luong, D. Langleben (Giessen, Berlin, Wuppertal, Germany; Bologna, Italy; Le Kremlin-Bicêtre, France; Sydney, Australia; La Jolla, Boston, United States Of America; Bollington, United Kingdom; Montreal, Canada). Impact of riociguat on health-related quality of life (HRQoL) in patients with pulmonary arterial hypertension (PAH). Eur Respir J 2013; 42: Suppl. 57, 3419

Member's Comments

No comment yet.

Related content which might interest you: Impact of riociguat on health-related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Impact of macitentan on the health-related quality of life (HRQoL) in pulmonary arterial hypertension (PAH): Results from a long-term randomised controlled trial Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Sildenafil improves health-related quality of life in pulmonary arterial hypertension (PAH) patients Source: Eur Respir J 2005; 26: Suppl. 49, 563s Year: 2005 Effects of tadalafil on health-related quality of life in patients with pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Health-related quality of life in patients with pulmonary arterial hypertension Source: Annual Congress 2011 - Clinical features of pulmonary hypertension Year: 2011 Relationship of quality of life and life expectancy with tolerance to physical exercises and cardio respiratory parameters in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Novel biomarkers and old parameters in clinical management of lung diseases Year: 2013 EmPHasis-10 is associated with clinical outcome measures in pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Relation of the novel pulmonary hypertension emPHasis10 quality of life score to markers of disease severity Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Measurement of quality of life in pulmonary hypertension and its significance Source: Eur Respir J 2006 Oct 01;28(4):808-815 Year: 2006 emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension Source: Eur Respir J 2014; 43: 1106-1113 Year: 2014 Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertension Source: Eur Respir J 2011; 38: 608-616 Year: 2011 EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR Source: Eur Respir J, 57 (2) 2000414; 10.1183/13993003.00414-2020 Year: 2021 Assessment of quality of life and social and economic impact of the disease in patients with pulmonary arterial hypertension in Germany – Data of the SANTANA-Study Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension Year: 2020 Health-related quality of life and disease progression in pulmonary arterial hypertension patients: a 3-year study Source: ERJ Open Res, 7 (3) 00617-2020; 10.1183/23120541.00617-2020 Year: 2021 Examination about what determine quality of life (QOL) and the association between QOL and therapeutic intervention for patients with chronic thromboembolitic pulmonary hypertension (CTEPH) Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Quality of life and physical functioning in chronic thromboembolic pulmonary hypertension (CTEPH):  the impact of treatment Source: International Congress 2017 – PAH and CTEPH Year: 2017 Impact of insomnia on exercise capacity and quality of life in patients with pulmonary arterial hypertension Source: International Congress 2017 – PAH and CTEPH Year: 2017 Pulmonary arterial hypertension: the burden of disease and impact on quality of life Source: Eur Respir Rev 2015; 24: 621-629 Year: 2015 Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1) Source: Eur Respir J 2010; 35: 118-123 Year: 2010 Physical activity (PA) in pulmonary arterial hypertension (PAH) can be predicted by questionnaire Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016